Ironwood to Focus on GI Diseases, Spins Off Cyclerion Therapeutics
- Posted by ISPE Boston
- On April 4, 2019
Ironwood Pharmaceuticals, a GI-focused healthcare company, has announced that it has completed the tax-free spin-off of its soluble guanylate cyclase (sGC) business, Cyclerion Therapeutics. Ironwood is executing on its strategy to drive growth as a GI-focused company, building upon its commercial success with Linzess and advancing its late-stage, first-in-category development candidates including IW-3718 for the […]
Read More